reboxetine has been researched along with atomoxetine hydrochloride in 10 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (atomoxetine hydrochloride) | Trials (atomoxetine hydrochloride) | Recent Studies (post-2010) (atomoxetine hydrochloride) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 1,386 | 306 | 788 |
| Protein | Taxonomy | reboxetine (IC50) | atomoxetine hydrochloride (IC50) |
|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bymaster, FP; Davis, RJ; McKinzie, DL; Nomikos, GG; Overshiner, CD; Perry, KW; Tzavara, ET; Witkin, JM; Wolff, M | 1 |
| Alexoff, D; Carter, P; Cosson, V; Ding, YS; Fowler, JS; Hubbard, B; Jayne, M; King, P; Learned-Coughlin, S; Logan, J; Muench, L; Schlyer, D; Shea, C; Telang, F; Volkow, ND; Wang, GJ; Xu, Y; Zabroski, J | 1 |
| Ikeda, K; Kobayashi, T; Washiyama, K | 1 |
| Robinson, ES | 1 |
| Coogan, AN; O'Keeffe, SM; Thome, J | 1 |
| Li, B; Li, X; Li, Y; Wang, P; Xue, W; Yang, F; Yao, X; Zheng, G; Zhu, F | 1 |
| Horder, J; Matthews, PRL; Pearce, M | 1 |
| Buchanan, GF; Dayton, KG; Kruse, SW; Purnell, BS; Rosner, JI | 1 |
| Ciucci, MR; Hoffmeister, JD; Kelm-Nelson, CA | 1 |
| Hu, X; Li, W; Pan, L | 1 |
2 review(s) available for reboxetine and atomoxetine hydrochloride
| Article | Year |
|---|---|
Selective noradrenaline reuptake inhibitors for schizophrenia.
Topics: Adrenergic Uptake Inhibitors; Adult; Atomoxetine Hydrochloride; Citalopram; Cognition; Humans; Morpholines; Quality of Life; Randomized Controlled Trials as Topic; Reboxetine; Schizophrenia; Serotonin and Noradrenaline Reuptake Inhibitors; Viloxazine | 2018 |
Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Humans; Norepinephrine; Reboxetine; Schizophrenia; Treatment Outcome | 2023 |
1 trial(s) available for reboxetine and atomoxetine hydrochloride
| Article | Year |
|---|---|
Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
Topics: Adrenergic Uptake Inhibitors; Adult; Algorithms; Atomoxetine Hydrochloride; Brain; Carbon Radioisotopes; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Male; Morpholines; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Propylamines; Radiopharmaceuticals; Reboxetine; Reproducibility of Results | 2007 |
7 other study(ies) available for reboxetine and atomoxetine hydrochloride
| Article | Year |
|---|---|
Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.
Topics: Acetylcholine; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Central Nervous System Stimulants; Cerebral Cortex; Cholinergic Fibers; Hippocampus; Male; Maze Learning; Methylphenidate; Microdialysis; Morpholines; Norepinephrine; Pattern Recognition, Visual; Propylamines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reboxetine; Receptors, Dopamine | 2006 |
Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Biophysics; Central Nervous System Depressants; Dose-Response Relationship, Drug; Drug Interactions; Electric Stimulation; Ethanol; Female; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Guanosine 5'-O-(3-Thiotriphosphate); Membrane Potentials; Microinjections; Morpholines; Oocytes; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Propylamines; Reboxetine; Receptor, Adenosine A1; Xenopus laevis | 2010 |
Blockade of noradrenaline re-uptake sites improves accuracy and impulse control in rats performing a five-choice serial reaction time tasks.
Topics: Adrenergic Uptake Inhibitors; Animals; Animals, Outbred Strains; Atomoxetine Hydrochloride; Attention; Choice Behavior; Dose-Response Relationship, Drug; Impulsive Behavior; Male; Methylphenidate; Morpholines; Propylamines; Rats; Reaction Time; Reboxetine; Serial Learning; Time Factors | 2012 |
The noradrenaline reuptake inhibitor atomoxetine phase-shifts the circadian clock in mice.
Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Atomoxetine Hydrochloride; Attention; Behavior, Animal; Circadian Rhythm; CLOCK Proteins; Darkness; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Morpholines; Propylamines; Proto-Oncogene Proteins c-fos; Reboxetine; Suprachiasmatic Nucleus | 2012 |
Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study.
Topics: Amino Acid Motifs; Antipsychotic Agents; Atomoxetine Hydrochloride; Binding Sites; Humans; Maprotiline; Molecular Docking Simulation; Molecular Dynamics Simulation; Morpholines; Neurotransmitter Uptake Inhibitors; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Reboxetine; Stereoisomerism; Structural Homology, Protein; Thermodynamics; Viloxazine | 2016 |
Effect of monoamine reuptake inhibition and α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Citalopram; Duloxetine Hydrochloride; Electroshock; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Prazosin; Reboxetine; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors; Sudden Unexpected Death in Epilepsy | 2019 |
Manipulation of vocal communication and anxiety through pharmacologic modulation of norepinephrine in the Pink1-/- rat model of Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Atomoxetine Hydrochloride; Disease Models, Animal; Humans; Male; Norepinephrine; Parkinson Disease; Protein Kinases; Rats; Rats, Long-Evans; Reboxetine; Vocalization, Animal | 2022 |